Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis

Table 1 Demography of the patients (mean ± SD)

	Non- antiviral (n = 38)	Antiviral (n = 79)	P value	Normal range
Gender (male/female)	30/8	62/17	1.000
Age (yr)	51.8 ± 10.3	50.4 ± 8.8	0.443
Median Child-Pugh score	8	8	0.887
Previous grade of EV (0/1/2/3)	21/0/6/11	41/4/18/16	0.330
Previous copies of HBVDNA (log10)	4.2 ± 1.1	4.6 ± 2.5	0.176	(-)
Previous hepatitis B e antigen (+/-)	24/14	46/33	0.689	(-)
Previous diameter of portal vein (mm)	11.8 ± 2.1	12.6 ± 2.2	0.392	< 10
Previous splenic section area (cm2)	35.3 ± 9.5	37.4 ± 13.2	0.384	< 20
GPT (IU/L)	49.7 ± 21.1	53.3 ± 64.9	0.315	5-40
GOT (IU/L)	48.1 ± 32.8	57.9 ± 56.2	0.231	5-40
TB (mmol/L)	26.7 ± 14.6	25.1 ± 15.5	0.635	3.4-17.1
ALB (g/L)	24.7 ± 4.9	25.4 ± 5.0	0.667	35-50
PT (s)	14.9 ± 2.5	16.5 ± 7.9	0.236	< 12
PLT (1012/L)	83.1 ± 41.8	78.7 ± 41.9	0.600	100-300
Endoscopic eradication (yes/no)	17/21	37/42	0.846
Propranolol (yes/no)	30/8	65/14	0.801

EV: Esophageal varices; HBV DNA: Hepatitis B virus DNA; GPT: Glutamic-pyruvic transaminase; GOT: Glutamic-oxaloacetic transaminase; TB: Total bilirubin; ALB: Serum albumin; PT: Prothrombin time; PLT: Platelet count.